Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …
recent results have shown that they could become a reality. Convincing data generated with …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
Blood‐based biomarkers for Alzheimer's disease
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Traumatic brain injury and risk of neurodegenerative disorder
Traumatic brain injury (TBI), particularly of greater severity (ie, moderate to severe), has
been identified as a risk factor for all-cause dementia and Parkinson's disease, with risk for …
been identified as a risk factor for all-cause dementia and Parkinson's disease, with risk for …
Designing the next-generation clinical care pathway for Alzheimer's disease
The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
has facilitated the development of biomarker-guided, pathway-based targeted therapies …
Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross‐sectional and longitudinal study in the AIBL cohort
Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …
Predicting amyloid PET and tau PET stages with plasma biomarkers
Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …